دورية أكاديمية
Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer
| العنوان: | Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer |
|---|---|
| المؤلفون: | Cortés, J., Baselga, J., Im, Y.-H., Im, S.-A., Pivot, X., Ross, G., Clark, E., Knott, A., Swain, S. M. |
| بيانات النشر: | Oxford University Press |
| سنة النشر: | 2013 |
| المجموعة: | HighWire Press (Stanford University) |
| مصطلحات موضوعية: | quality of life and supportive care |
| الوصف: | Background The phase III CLEOPATRA study demonstrated that combining pertuzumab with trastuzumab plus docetaxel significantly improves progression-free and overall survival in previously untreated HER2-positive metastatic breast cancer. Here, we report health-related quality-of-life (HRQoL) results from CLEOPATRA. Patients and methods Participants were randomly assigned to pertuzumab or placebo, each given with trastuzumab plus docetaxel every 3 weeks. Pertuzumab and trastuzumab were administered until progression and six or more docetaxel cycles were recommended. Time from randomization to a ≥5-point decrease in Trial Outcome Index-Physical/Functional/Breast (TOI-PFB) of the Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaire was analyzed as a prespecified secondary end point. A post hoc exploratory analysis investigated time to ≥2-point deterioration in Breast Cancer Subscale (BCS) score. Results Time to ≥5-point decline in TOI-PFB did not differ significantly between the pertuzumab and placebo arms [hazard ratio (HR), 0.97; P = 0.7161]. The median times to TOI-PFB deterioration were 18.4 and 18.3 weeks, respectively (approximately six cycles). The mean TOI-PFB declined slightly until week 18 and recovered thereafter. Pertuzumab increased time until BCS deterioration versus placebo (median 26.7 versus 18.3 weeks; HR, 0.77; P = 0.0061). Conclusions Combining pertuzumab with trastuzumab and docetaxel had no adverse impact on HRQoL and may prolong time to worsening of breast cancer-specific symptoms. |
| نوع الوثيقة: | text |
| وصف الملف: | text/html |
| اللغة: | English |
| العلاقة: | http://annonc.oxfordjournals.org/cgi/content/short/24/10/2630Test; http://dx.doi.org/10.1093/annonc/mdt274Test |
| DOI: | 10.1093/annonc/mdt274 |
| الإتاحة: | https://doi.org/10.1093/annonc/mdt274Test http://annonc.oxfordjournals.org/cgi/content/short/24/10/2630Test |
| حقوق: | Copyright (C) 2013, European Society for Medical Oncology |
| رقم الانضمام: | edsbas.7C597D7F |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/annonc/mdt274 |
|---|